NEW YORK – The World Health Organization announced today from Geneva it is ready to begin implementing the initial phase of testing new Ebola medical therapies and experimental vaccines.
Health facilities are being set up now in Liberia to take blood serum
from Ebola survivors for transfusions in the treatment of infected
patients. Facilities in Sierra Leone and Guinea will soon follow.
WHO also announced the French government is ready to begin in Guinea
clinical trials of a Japanese-developed Ebola vaccine called Favipiravi.
Known as T-705, it is marketed by Toyama Chemical under the trade name
Avigan.
WHO also announced human Phase 1 clinical trials of two experimental
Ebola vaccines are expected to begin by the end of October or the
beginning of November.
WHO is ready to test on humans the two frontrunner experimental
vaccines it approved in a conference in Geneva Sept. 4-5 with nearly 200
medical doctors and experts invited from around the world.
One of the vaccines, cAd3-ZEBOV, has been developed by
GlaxoSmithKline in collaboration with the U.S. National Institute of
Allergy and Infectious Diseases. It uses a chimpanzee-derived adenovirus
vector with an Ebola virus gene inserted.
The second, rVSV-ZEBOV. was developed by the Public Health Agency of
Canada in Winnipeg. The license for commercialization of the Canadian
vaccine is held by an American company, NewLink Genetics, located in
Ames, Iowa. The vaccine uses an attenuated or weakened vesicular
stomatitis virus, a pathogen found in livestock. One of its genes is
replaced by an Ebola virus gene.
Read more at http://www.wnd.com/2014/10/who-begins-testing-new-ebola-treatment/#jT7Rk0PJzkF3KD5q.99
No comments:
Post a Comment